Remote stroke surgery robot receives funding

Remedy Robotics, a healthcare and physical AI company building robotic systems for cardiovascular care and endovascular intervention, has raised $62 million in Series B funding.

The funding will drive a pivotal clinical trial with the University of California and advance the company toward FDA approval for neurovascular intervention.

Remedy will deploy prototype N1 Systems across its clinical partner network, including via strategic partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance. The company will also continue to advance the system’s AI capabilities and autonomous functions. 
Dr David Bell, CEO and co-founder of Remedy Robotics, said: ‘Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common. This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography.’

Remedy is finalising development of the N1 System, an AI-enabled robotic platform and software suite that uses machine learning to:
• Analyse preoperative imaging
• Simulate cases in advance
• Provide real-time 3D-2D image registration
• Complete entire endovascular procedures robotically. 

Designed for on-site, remote, or autonomous operation, the system has the potential to dramatically expand access to and improve the quality of specialised neurovascular, coronary, and peripheral vascular care. 

Remedy works with more than 100 hospitals worldwide and is among a small group of physical AI companies bringing robotics into real-world clinical use. 
In October 2025, Remedy announced that it had successfully completed the world’s first remote neurointerventional procedures using the N1 System. 

Jake Sganga, CTO and co-founder of Remedy Robotics, said: ‘This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features, including full autonomy. We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.’

Published: 20.11.2026
surgery
connecting surgeons. shaping the future
AboutContact
Register
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram
Send this to a friend